BIOMAGSCAR

Biodegradable Magnetic Stent for Coronary Artery Luminal Regeneration

Coordinatore	UNIVERSITY COLLEGE LONDON    more  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Kimberly Cognome: Cornfield Email: send email Telefono: +44 2031083033 Fax: +44 20 78132849
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.biomagscar.eu/
Totale costo	6˙816˙054 €
EC contributo	5˙299˙478 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2011-two-stage
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01   -   2015-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE LONDON  Organization address address: GOWER STREET city: LONDON postcode: WC1E 6BT contact info Titolo: Ms. Nome: Kimberly Cognome: Cornfield Email: send email Telefono: +44 2031083033 Fax: +44 20 78132849	UK (LONDON)	coordinator	718˙198.00
2	QUALIMED INNOVATIVE MEDIZINPRODUKTE GMBH  Organization address address: BOSCHSTRASSE 16 city: WINSEN postcode: 21423 contact info Titolo: Mr. Nome: Georg Cognome: Göllmann Email: send email Telefono: +49 4171 6578 205 Fax: +49 4171 6578 11	DE (WINSEN)	participant	981˙252.00
3	Nome Ente NON disponibile  Organization address address: YLIOPISTONRANTA 1 E city: Kuopio postcode: 70211 contact info Titolo: Ms. Nome: Tiina Cognome: Reinikainen Email: send email Telefono: +358 40 5121200 Fax: +358 17 162131	FI (Kuopio)	participant	885˙990.00
4	MAGNUS INVENTION MANAGEMENT LTD  Organization address address: GLASSLYN ROAD 39 city: LONDON postcode: N8 8RJ contact info Titolo: Mr. Nome: Mads Cognome: Asprem Email: send email Telefono: +44 7887628631	UK (LONDON)	participant	857˙660.00
5	QUEEN MARY UNIVERSITY OF LONDON  Organization address address: 327 MILE END ROAD city: LONDON postcode: E1 4NS contact info Titolo: Ms. Nome: Tanya Cognome: Szendeffy Email: send email Telefono: +44 20 7882 7266 Fax: +44 20 7882 7276	UK (LONDON)	participant	752˙762.00
6	YALE UNIVERSITY  Organization address address: WHITNEY AVENUE 155 ROOM 214 city: NEW HAVEN postcode: 06520 8337 contact info Titolo: Mr. Nome: Jeffrey Cognome: Mcguinness Email: send email Telefono: +1 203 785 5536	US (NEW HAVEN)	participant	730˙088.00
7	EURAM LIMITED  Organization address address: "Tower House, Lucy Tower Street" city: LINCOLN postcode: LN1 1XW contact info Titolo: Mr. Nome: Andrew Cognome: Banasik Email: send email Telefono: +44 1159 811335 Fax: +44 1159 541 295	UK (LINCOLN)	participant	373˙528.00
8	FINVECTOR VISION THERAPIES LIMITED  Organization address address: WHITFIELD STREET 44-46 FLOOR 4 city: LONDON postcode: W1T2RJ contact info Titolo: Mr. Nome: Russell Cognome: Banks Email: send email Telefono: +44 207 388 7722 Fax: +44 20 7388 7805	UK (LONDON)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'By 2010 1.5 million stents per year will be deployed in Europe. Although outcome for patients has improved, stents still fail because of the occurrence of restenosis and thrombosis at the site of implantation. While drug eluting stents have helped to reduce the problem of restenosis, neointimal proliferation causing restenosis can still occur. Additional concerns exist regarding drug eluting stents as there appears to be a small but real increase in late and very late stent thrombosis, particularly after discontinuation of antiplatelet therapy. The novel concept we propose is use of a biodegradable magnetised stent (BMS) to deliver a novel biological therapy offering regenerative medicine solutions to the coronary artery vessel wall. Specifically we will develop the stent technology as a platform to attract autologous progenitor cells tagged in vitro with iron nanoparticles. Once deployed, the cells will be attracted to the already implanted BMS and proliferate to form a new endothelium. We will also use over-expression of the NRP1 gene in the artery wall where it will dimerise with NRP1 receptors on the deployed cells. The NRP1 gene will be transfected by adenovirus delivered from the wall of the BMS. Over time the BMS will undergo a predictable degradation to leave a wholly biological artery through regeneration of native tissues. Currently, about 12,000 European Citizens a year suffer from late in-stent thrombosis and 120,000 from restenosis. With the knowledge and technologies developed through the BIOMAGSCAR project we aim to halve this number of patients and save 66,000 people from unnecessary suffering, saving the European healthcare system €275 million p.a. in direct costs, only 10% of the total associated costs. Our consortium includes a vascular disease therapy company, a stent research and manufacturing company, four universities and a specialist in innovative technology investment, all of whom believe our technology will dramatically change this field.'

Introduzione (Teaser)

Insertion of a stent or tube for treatment of coronary artery disease may result in thrombosis. An EU-funded project is developing a new biodegradable magnetic stent (BMS) to regenerate the damaged vessel.